Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission February 20, 2025
Photys presents recent data at Keystone Symposia for Proximity-Based Therapeutics on p53-Y220C-BET-bifunctionals that drive death of cancer cells in vitro and in vivo. February 20, 2025
Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases December 18, 2024
